Asbestos exposure and mesothelioma mortality among atomic veterans.
Autorzy:
Till JE; Risk Assessment Corporation, Neeses, SC, USA. Beck HL; New York, NY, USA. Boice JD Jr; National Council on Radiation Protection and Measurements, Bethesda, MD, USA.; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. Mohler HJ; Bridger Scientific, Inc, Belgrade, MT, USA. Mumma MT; International Epidemiology Institute, Rockville, MD, USA. Aanenson JW; Scientific Consulting, Inc, Freeman, SD, USA. Grogan HA; Cascade Scientific, Inc, Bend, OR, USA.
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia.
Autorzy:
Buccisano F; Hematology, Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy. . Dillon R; Department of Medical and Molecular Genetics, King's College, London SE1 9RT, UK. . FreemanSD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK. S.Freeman@bham.ac.uk. Venditti A; Hematology, Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy. .
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2018 Jun 26; Vol. 10 (7). Date of Electronic Publication: 2018 Jun 26.
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.
Autorzy:
Khan N; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, United Kingdom. Hills RK; Department of Haematology, Cardiff University School of Medicine, University Hospital Wales, Cardiff, United Kingdom. Knapper S; Department of Haematology, Cardiff University School of Medicine, University Hospital Wales, Cardiff, United Kingdom. Steadman L; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, United Kingdom. Qureshi U; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, United Kingdom. Rector JL; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, United Kingdom. Bradbury C; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom. Russell NH; Centre for Clinical Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom. Vyas P; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom. Burnett AK; Department of Haematology, Cardiff University School of Medicine, University Hospital Wales, Cardiff, United Kingdom. Grimwade D; Department of Medical and Molecular Genetics, King's College London School of Medicine, Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom. Hole PS; Department of Haematology, Cardiff University School of Medicine, University Hospital Wales, Cardiff, United Kingdom. FreemanSD; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Sep 26; Vol. 11 (9), pp. e0163291. Date of Electronic Publication: 2016 Sep 26 (Print Publication: 2016).
Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.
Autorzy:
Bradbury C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK. Houlton AE; 1] Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK [2] Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK. Akiki S; West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, UK. Gregg R; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK. Rindl M; West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, UK. Khan J; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK. Ward J; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK. Khan N; Department of Clinical Immunology, University of Birmingham, Birmingham, UK. Griffiths M; West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, UK. Nagra S; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK. Hills R; Department of Haematology, Cardiff University, Cardiff, UK. Burnett A; Department of Haematology, Cardiff University, Cardiff, UK. Russell N; Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, UK. Vyas P; 1] MRC Molecular Haematology Unit, WIMM, University of Oxford, Oxford, UK [2] Department of Haematology, Radcliffe Hospitals NHS Trust, Oxford, UK. Grimwade D; 1] Department of Medical & Molecular Genetics, King's College London, Faculty of Life Sciences and Medicine, London, UK [2] Department of Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK. Craddock C; 1] Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK [2] Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK. FreemanSD; 1] Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK [2] Department of Clinical Immunology, University of Birmingham, Birmingham, UK.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Apr; Vol. 29 (4), pp. 988-91. Date of Electronic Publication: 2014 Nov 26.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
